{"product_id":"azn-bcg-matrix","title":"(AZN) AstraZeneca PLC BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis AstraZeneca PLC BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already includes a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTagrisso \u0026gt;$5B EGFR NSCLC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTagrisso is AstraZeneca PLC’s top oncology brand and a global standard for EGFR-mutated non-small cell lung cancer. It posted $6.6 billion in 2024 sales, and its move from metastatic use into earlier-stage disease has widened the addressable market. That mix of strong revenue and label expansion fits a Star in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFarxiga \u0026gt;$7B CKD HF T2D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFarxiga is AstraZeneca PLC’s $7.7B franchise, with 2024 sales above the $7B mark, so it is one of the company’s biggest cash drivers. \u003c\/p\u003e\n\u003cp\u003eIts use spans type 2 diabetes, heart failure and chronic kidney disease, and the SGLT2 class keeps adding new patient groups as evidence builds. \u003c\/p\u003e\n\u003cp\u003eHigh demand, broad label use and a leading market position make Farxiga a clear Star in AstraZeneca PLC’s BCG Matrix. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImfinzi \u0026gt;$4B immuno-oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImfinzi stayed a Star for AstraZeneca PLC, with annual sales above $4B as it expanded across lung and bladder cancer. The franchise now spans multiple settings, including earlier-stage and combo use, which keeps demand rising in a large immuno-oncology market. That breadth supports continued growth, not just a one-off launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnhertu \u0026gt;$3B HER2 cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnhertu has crossed the $3 billion sales mark and remains one of AstraZeneca PLC's fastest-growing oncology assets through the Daiichi Sankyo deal. Its use in HER2-positive breast and lung cancer keeps expanding, which signals strong share gains in a large, high-value market.\u003c\/p\u003e\n\u003cp\u003eThe drug's rapid uptake supports Star status in the BCG Matrix because it combines high growth with rising commercial scale. In 2025, the HER2 segment stayed one of the most important growth pools in oncology, and Enhertu kept taking share in both second-line and earlier settings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual sales already above $3 billion\u003c\/li\u003e\n\u003cli\u003eGrowing in breast and lung cancer\u003c\/li\u003e\n\u003cli\u003eBacked by AstraZeneca and Daiichi Sankyo\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCalquence \u0026gt;$2B BTK hematology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCalquence stayed a Star for AstraZeneca PLC, with 2025 sales above $2 billion and strong demand in chronic lymphocytic leukemia and related B-cell cancers. \u003c\/p\u003e\n\u003cp\u003eIt is gaining physician adoption in a large hematology market, and AstraZeneca PLC keeps investing in trials and promotion to defend share. \u003c\/p\u003e\n\u003cp\u003eThat mix of high growth, scale, and continued spend fits the Star bucket in the BCG Matrix. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 sales: above $2 billion\u003c\/li\u003e\n\u003cli\u003eCore use: CLL and related indications\u003c\/li\u003e\n\u003cli\u003eStrong adoption supports growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstraZeneca’s Star Drugs Are Driving Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars in AstraZeneca PLC’s BCG Matrix are Tagrisso, Farxiga, Imfinzi, Enhertu, and Calquence. In 2025, Farxiga topped $7B, Tagrisso was $6.6B in 2024, Imfinzi was above $4B, Enhertu passed $3B, and Calquence was above $2B. Their mix of high sales and strong growth keeps them in the Star bucket.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDrug\u003c\/th\u003e\n\u003cth\u003e2025\/2024 sales\u003c\/th\u003e\n\u003cth\u003eStar signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFarxiga\u003c\/td\u003e\n\u003ctd\u003e$7.7B\u003c\/td\u003e\n\u003ctd\u003eBroad use, still growing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImfinzi\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$4B\u003c\/td\u003e\n\u003ctd\u003eExpanding oncology labels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnhertu\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$3B\u003c\/td\u003e\n\u003ctd\u003eFast share gains\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCalquence\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$2B\u003c\/td\u003e\n\u003ctd\u003eRising hematology use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAstraZeneca PLC BCG Matrix: identifies Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page AstraZeneca PLC BCG Matrix highlighting each quadrant for quick, C-level decision-making\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for AstraZeneca PLC, boosting credibility and helping decision-makers verify key assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSymbicort legacy inhaler\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSymbicort is a mature respiratory brand with long global use and low market growth. It now faces heavy generic competition, so its growth has slowed, but it still throws off steady cash for AstraZeneca PLC. That mix of weak growth and ongoing cash generation makes Symbicort a classic Cash Cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoliris orphan complement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSoliris, approved in 2007, is AstraZeneca PLC's classic rare-disease cash cow: a mature C5 inhibitor with a large, sticky patient base in PNH and aHUS. Even with Ultomiris and biosimilar pressure, it still throws off meaningful cash from a franchise that has been built over 18 years. Its role is now harvest, not growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLynparza \u0026gt;$2B PARP leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLynparza remains AstraZeneca PLC’s PARP leader, with 2024 sales of $2.9bn and a broad global oncology footprint. The category is more mature than newer launches, but Lynparza still holds the leading share in a large, repeat-use cancer franchise. That mix of scale, reach, and cash generation makes it a clear Cash Cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBrilinta \u0026gt;$1B antiplatelet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrilinta is a mature antiplatelet brand in a slow-growing cardiovascular market. AstraZeneca said it has topped $1bn in annual sales, but US generic pressure has already cut growth, so the drug still adds cash even as the franchise ages.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature brand\u003c\/li\u003e\n\u003cli\u003eLow-growth category\u003c\/li\u003e\n\u003cli\u003eStill cash generative\u003c\/li\u003e\n\u003cli\u003eFacing generic erosion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis makes Brilinta a clear Cash Cow in AstraZeneca PLC's BCG matrix: it supports earnings and funding, but no longer drives major growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFasenra \u0026gt;$1B severe asthma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFasenra is a mature Cash Cow for AstraZeneca PLC, with annual sales above $1B and a defined base in severe eosinophilic asthma. It serves a chronic, specialist-treated population, so revenue is steadier than newer launches, even if growth has slowed versus AstraZeneca PLC’s newer immunology and oncology drugs.\u003c\/p\u003e\n\u003cp\u003eIts established brand, repeat dosing, and broad payer access support durable cash flow. In BCG terms, Fasenra fits a Cash Cow because it still throws off strong revenue from a well-known respiratory franchise, but it no longer needs the same growth spend as AstraZeneca PLC’s faster-rising assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual sales stay above $1B\u003c\/li\u003e\n\u003cli\u003eStable, defined asthma patient base\u003c\/li\u003e\n\u003cli\u003eSlower growth, strong cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstraZeneca’s Cash Cows Still Fund Growth, But Erosion Is Creeping In\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAstraZeneca PLC’s Cash Cows are mature brands with slow growth but strong cash flow: Symbicort, Soliris, Lynparza, Brilinta, and Fasenra. Lynparza posted $2.9bn in 2024 sales, and Fasenra stayed above $1bn, while Brilinta and Symbicort face generic erosion. These drugs still fund the portfolio, but growth is limited.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLynparza\u003c\/td\u003e\n\u003ctd\u003eLeader\u003c\/td\u003e\n\u003ctd\u003e$2.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFasenra\u003c\/td\u003e\n\u003ctd\u003eCash flow\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrilinta\u003c\/td\u003e\n\u003ctd\u003eGeneric pressure\u003c\/td\u003e\n\u003ctd\u003e$1bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAstraZeneca PLC Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe AstraZeneca PLC BCG Matrix preview you see is the exact same document you’ll receive after purchase. There are no demo pages or hidden changes—just the full, ready-to-use report. Once purchased, the file is instantly available for download and use. What you preview here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaxzevria COVID-19 vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVaxzevria is no longer a growth engine for AstraZeneca PLC. COVID-19 vaccine demand has fallen far below the 2021 peak, and AstraZeneca no longer reports Vaxzevria as a material revenue driver. With weak demand and a small market share, it fits the Dog quadrant in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrestor generic statin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCrestor, AstraZeneca PLC’s rosuvastatin brand, is a mature statin with little remaining exclusivity value. Generic competition has pushed prices down hard and cut share; in the U.S., rosuvastatin is now sold mainly as low-cost generics, with AstraZeneca’s branded sales only a small residual line item. It fits the Dogs box: low growth, low share, and weak cash upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeroquel generic antipsychotic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeroquel (quetiapine) is a legacy AstraZeneca PLC psychiatric brand that has faced heavy generic erosion after patent expiry, so branded sales have been in long-term decline. The antipsychotic market is mature, and the franchise has little remaining growth headroom as low-cost generics dominate prescriptions. In BCG terms, that puts Seroquel in the Dog bucket: low growth, weak competitive position, and limited capital appeal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNexium generic PPI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNexium (esomeprazole) is now an off-patent PPI in a mature acid-suppression market, so branded pricing power is weak and low-cost generics dominate. Its US exclusivity ended in 2014, and the class is crowded with cheap omeprazole and pantoprazole options, so AstraZeneca PLC gets little strategic lift from the brand. That makes Nexium a clear Dog in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOff-patent and commoditized\u003c\/li\u003e\n\u003cli\u003eWeak branded share\u003c\/li\u003e\n\u003cli\u003eLow growth, low margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eArimidex generic aromatase inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArimidex, AstraZeneca PLC’s anastrozole brand, is now a mature breast-cancer drug with little growth left; AstraZeneca’s 2025 reporting no longer treats it as a material driver, while generic anastrozole dominates on price. The key patent expired years ago, so substitution has steadily eroded branded demand. That is classic low-growth, low-share Dog territory in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder brand, weak growth\u003c\/li\u003e\n\u003cli\u003ePatent loss cut pricing power\u003c\/li\u003e\n\u003cli\u003eGeneric anastrozole now leads\u003c\/li\u003e\n\u003cli\u003eFits Dogs in BCG\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstraZeneca’s Aging Brands Face Generic Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThese AstraZeneca PLC brands are Dogs because they are mature, off-patent, and face generic-led pricing pressure. Vaxzevria, Crestor, Seroquel, Nexium, and Arimidex now add little growth and have weak share in low-growth markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaxzevria\u003c\/td\u003e\n\u003ctd\u003eDemand collapse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrestor\u003c\/td\u003e\n\u003ctd\u003eGeneric erosion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeroquel\u003c\/td\u003e\n\u003ctd\u003ePatent loss\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexium\u003c\/td\u003e\n\u003ctd\u003eOff-patent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eArimidex\u003c\/td\u003e\n\u003ctd\u003eWeak growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTezspire severe asthma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTezspire is in a fast-growing severe-asthma space, where biologic sales are already in the $10bn-plus range and rivals like Dupixent, Nucala, Fasenra, and Xolair have bigger franchises. AstraZeneca is still building share, even as Tezspire's 2024 sales topped $1bn, so the asset has clear growth upside but limited scale versus leaders. That mix of high market growth and lower market share makes Tezspire a Question Mark in AstraZeneca PLC's BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSaphnelo lupus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSaphnelo is a Question Mark in AstraZeneca PLC’s BCG Matrix: it targets systemic lupus erythematosus, a disease affecting about 3.4 million people worldwide, with clear unmet need. Uptake is still early versus AstraZeneca PLC’s larger immunology brands, so revenue share remains modest. The drug has real growth potential, but its market position is not yet proven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTruqap breast cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTruqap (capivasertib) is a newer breast-cancer launch for AstraZeneca PLC in a huge oncology market, but it is still early in uptake, so it fits a Question Mark. In CAPItello-291, Truqap plus fulvestrant cut disease progression or death risk by 40% overall and by 50% in PIK3CA\/AKT1\/PTEN-altered tumors, which supports growth. It still needs fast share gains against entrenched CDK4\/6 and PI3K rivals to move toward Star status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWainzua ATTR-PN\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWainua is AstraZeneca PLC’s eplontersen for hereditary transthyretin amyloidosis with polyneuropathy, a rare, high-value niche that still had only about 5,000 diagnosed patients in the U.S. in 2025. The ATTR-PN market is expanding fast as diagnosis improves, but AstraZeneca’s share is still early, so Wainua fits a Question Mark in the BCG Matrix. \u003c\/p\u003e\n\u003cp\u003eIn 2025, AstraZeneca and Ionis were still building uptake after the U.S. launch, while rivals in ATTR therapy had already reached much larger installed bases, so Wainua needs heavy promotion and access wins to convert growth into share. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare disease, high price, high growth.\u003c\/li\u003e\n\u003cli\u003eLow current share, still scaling.\u003c\/li\u003e\n\u003cli\u003eNeeds proof to become a Star.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVoydeya PNH\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVoydeya (danicopan) targets complement-mediated disease in paroxysmal nocturnal hemoglobinuria, a niche but high-value rare-disease market. AstraZeneca PLC’s brand is still early in commercialization, so current share is low even as adoption can grow fast if add-on use to C5 therapy expands. That mix of small base and clear upside fits a Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare-disease niche\u003c\/li\u003e\n\u003cli\u003eEarly sales ramp\u003c\/li\u003e\n\u003cli\u003eLow share, high upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstraZeneca’s Question Marks: Big Potential, Small 2025 Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTezspire, Saphnelo, Truqap, Wainua, and Voydeya are AstraZeneca PLC Question Marks: each sits in a growing, high-value market, but 2025 sales and share are still small versus bigger rivals. Tezspire passed $1bn in 2024 sales, yet Dupixent and other biologics still lead. Truqap, Wainua, and Voydeya are still early launches, so they need faster uptake to turn growth into scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTezspire\u003c\/td\u003e\n\u003ctd\u003e$1bn+ 2024 sales\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaphnelo\u003c\/td\u003e\n\u003ctd\u003eEarly lupus uptake\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTruqap\u003c\/td\u003e\n\u003ctd\u003eEarly breast-cancer ramp\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWainua\u003c\/td\u003e\n\u003ctd\u003e~5,000 U.S. diagnosed patients\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVoydeya\u003c\/td\u003e\n\u003ctd\u003eEarly PNH launch\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234110513417,"sku":"azn-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/azn-bcg-matrix.webp?v=1785712343","url":"https:\/\/dcfanalyst.com\/products\/azn-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}